Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Solitary Fibrous Tumors 1Sarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 58Filgrastim 37Radiotherapy 31Busulfan 28fludarabine phosphate 26Antilymphocyte Serum 25Cyclosporine 24Peripheral Blood Stem Cell Transplantation 23Etoposide 22Methotrexate 20Melphalan 18Mycophenolic Acid 17Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Vincristine 13Cytarabine 13Tacrolimus 12Rituximab 11Whole-Body Irradiation 9Thiotepa 9Prednisone 9Doxorubicin 8Leucovorin 7sargramostim 6aldesleukin 6Granulocyte Colony-Stimulating Factor 6Psychiatric Rehabilitation 5Daunorubicin 5pembrolizumab 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Suspensions × Sarcoma × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡